These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12728858)

  • 21. Drug cost. States concerned about Fuzeon.
    AIDS Policy Law; 2003 Apr; 18(7):5. PubMed ID: 12728848
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
    Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
    N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Strategies for combating resistances in HIV therapy--an exemplifying case].
    Stoehr A
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
    [No Abstract]   [Full Text] [Related]  

  • 24. T-20 (Fuzeon) gets priority review.
    AIDS Treat News; 2002 Oct; (384):4-5. PubMed ID: 12434762
    [No Abstract]   [Full Text] [Related]  

  • 25. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

  • 26. Enfuvirtide (Fuzeon): the first fusion inhibitor.
    Williams IG
    Int J Clin Pract; 2003 Dec; 57(10):890-7. PubMed ID: 14712892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor.
    Cervia JS; Smith MA
    Clin Infect Dis; 2003 Oct; 37(8):1102-6. PubMed ID: 14523775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-HIV agents. T-20 shows long-term effectiveness and safety.
    TreatmentUpdate; 2005; 17(5):8-9. PubMed ID: 17225280
    [No Abstract]   [Full Text] [Related]  

  • 29. [Enfuvirtide, the first representative of a new class of drugs for the treatment of HIV infection : HIV fusion inhibitors].
    Koopmans PP
    Ned Tijdschr Geneeskd; 2003 Sep; 147(36):1726-9. PubMed ID: 14520797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-HIV agents. T-20 (enfurvirtide, Fuzeon).
    TreatmentUpdate; 2005; 17(1):5-6. PubMed ID: 17225316
    [No Abstract]   [Full Text] [Related]  

  • 31. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
    [No Abstract]   [Full Text] [Related]  

  • 32. Enfuvirtide (Fuzeon).
    Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three new drugs approved by FDA.
    Hoyt G
    Surviv News (Atlanta Ga); 2003; ():13, 20. PubMed ID: 14696579
    [No Abstract]   [Full Text] [Related]  

  • 34. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor.
    Poveda E; Rodés B; Toro C; Martín-Carbonero L; Gonzalez-Lahoz J; Soriano V
    AIDS; 2002 Sep; 16(14):1959-61. PubMed ID: 12351957
    [No Abstract]   [Full Text] [Related]  

  • 36. 9th National Retrovirus Conference: new treatments, new choices.
    Laurence J
    AIDS Patient Care STDS; 2002 May; 16(5):193-5. PubMed ID: 12055025
    [No Abstract]   [Full Text] [Related]  

  • 37. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
    Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
    Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-20: a model for novel anti-HIV drugs in development.
    Laurence J
    AIDS Read; 2002 Nov; 12(11):469-70. PubMed ID: 12494906
    [No Abstract]   [Full Text] [Related]  

  • 39. The fusion inhibitor enfuvirtide in recent antiretroviral strategies.
    Makinson A; Reynes J
    Curr Opin HIV AIDS; 2009 Mar; 4(2):150-8. PubMed ID: 19339955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA notifications. Enfuvirtide has new instructions.
    AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.